141 related articles for article (PubMed ID: 7694271)
21. Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice.
Yeeprae W; Kawakami S; Higuchi Y; Yamashita F; Hashida M
J Drug Target; 2005; 13(8-9):479-87. PubMed ID: 16332573
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice.
Kaneo Y; Uemura T; Tanaka T; Kanoh S; Matsuoka A
Biol Pharm Bull; 1995 Nov; 18(11):1544-7. PubMed ID: 8593476
[TBL] [Abstract][Full Text] [Related]
23. Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery.
Thambi T; You DG; Han HS; Deepagan VG; Jeon SM; Suh YD; Choi KY; Kim K; Kwon IC; Yi GR; Lee JY; Lee DS; Park JH
Adv Healthc Mater; 2014 Nov; 3(11):1829-38. PubMed ID: 24753360
[TBL] [Abstract][Full Text] [Related]
24. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes.
Managit C; Kawakami S; Yamashita F; Hashida M
J Pharm Sci; 2005 Oct; 94(10):2266-75. PubMed ID: 16136555
[TBL] [Abstract][Full Text] [Related]
25. Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency.
Nishikawa M; Hirabayashi H; Takakura Y; Hashida M
Pharm Res; 1995 Feb; 12(2):209-14. PubMed ID: 7784335
[TBL] [Abstract][Full Text] [Related]
26. Control of in vivo fate of albumin derivatives utilizing combined chemical modification.
Fujita T; Nishikawa M; Ohtsubo Y; Ohno J; Takakura Y; Sezaki H; Hashida M
J Drug Target; 1994; 2(2):157-65. PubMed ID: 8069594
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the T cell response to beta-lactoglobulin by conjugation with carboxymethyl dextran.
Kobayashi K; Yoshida T; Takahashi K; Hattori M
Bioconjug Chem; 2003; 14(1):168-76. PubMed ID: 12526706
[TBL] [Abstract][Full Text] [Related]
28. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine).
Mahato RI; Takemura S; Akamatsu K; Nishikawa M; Takakura Y; Hashida M
Biochem Pharmacol; 1997 Mar; 53(6):887-95. PubMed ID: 9113108
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.
Groothuis DR; Benalcazar H; Allen CV; Wise RM; Dills C; Dobrescu C; Rothholtz V; Levy RM
Brain Res; 2000 Feb; 856(1-2):281-90. PubMed ID: 10677637
[TBL] [Abstract][Full Text] [Related]
30. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer.
Corot C; Schaefer M; Beauté S; Bourrinet P; Zehaf S; Bénizé V; Sabatou M; Meyer D
Acta Radiol Suppl; 1997; 412():91-9. PubMed ID: 9240087
[TBL] [Abstract][Full Text] [Related]
31. Extending insulin action in vivo by conjugation to carboxymethyl dextran.
Baudys M; Letourneur D; Liu F; Mix D; Jozefonvicz J; Kim SW
Bioconjug Chem; 1998; 9(2):176-83. PubMed ID: 9548532
[TBL] [Abstract][Full Text] [Related]
32. Intracellular disposition of polysaccharides in rat liver parenchymal and nonparenchymal cells.
Tanaka T; Fujishima Y; Hanano S; Kaneo Y
Int J Pharm; 2004 Nov; 286(1-2):9-17. PubMed ID: 15500998
[TBL] [Abstract][Full Text] [Related]
33. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice.
Toyoshima S; Fukuma M; Seto Y; Fujita H; Fukushima K; Tomioka H; Sakurai T; Sugimoto Y; Yagi T; Hoshino T; Sowa T
Gan; 1981 Feb; 72(1):19-29. PubMed ID: 7274645
[TBL] [Abstract][Full Text] [Related]
34. Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice.
Akamatsu K; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1999 Sep; 290(3):1242-9. PubMed ID: 10454500
[TBL] [Abstract][Full Text] [Related]
35. Liver-targeted drug delivery using HepDirect prodrugs.
Erion MD; van Poelje PD; Mackenna DA; Colby TJ; Montag AC; Fujitaki JM; Linemeyer DL; Bullough DA
J Pharmacol Exp Ther; 2005 Feb; 312(2):554-60. PubMed ID: 15340017
[TBL] [Abstract][Full Text] [Related]
36. Studies on acyclovir-dextran conjugate: synthesis and pharmacokinetics.
Tu J; Zhong S; Li P
Drug Dev Ind Pharm; 2004; 30(9):959-65. PubMed ID: 15554220
[TBL] [Abstract][Full Text] [Related]
37. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics.
Hirata K; Maruyama T; Watanabe H; Maeda H; Nakajou K; Iwao Y; Ishima Y; Katsumi H; Hashida M; Otagiri M
J Control Release; 2010 Jul; 145(1):9-16. PubMed ID: 20304018
[TBL] [Abstract][Full Text] [Related]
38. Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo.
Dong L; Gao S; Diao H; Chen J; Zhang J
J Biomed Mater Res A; 2008 Mar; 84(3):777-84. PubMed ID: 17635017
[TBL] [Abstract][Full Text] [Related]
39. Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine.
Biessen EA; Beuting DM; Vietsch H; Bijsterbosch MK; Van Berkel TJ
J Hepatol; 1994 Nov; 21(5):806-15. PubMed ID: 7890898
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice.
Masuda H; Takakura Y; Hashida M
Biochim Biophys Acta; 1999 Feb; 1426(3):420-8. PubMed ID: 10076058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
